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1101-46 First Human Experience With the ABT-578 Eluting 
Phosphorylcholine Polymer Stent: A Serial Volumetric 
Intravascular Ultrasound Analysis From the PREFER 
Trial
Ryota Sakurai, Yoichiro Hongo, John Ormiston, Robert J. Whitbourn, Ian Meredith, 
Yasuhiro Honda, Paul G. Yock, Peter J. Fitzgerald, The PREFER Trial Investigators, 
Stanford University, Stanford, CA, Green Lane Hospital, Auckland, New Zealand
Background: ABT-578, an analog of rapamycin, is an anti-proliferative agent with prom-
ising preclinical study results. PREFER is a multicenter, non-randomized, single-arm,
feasibility trial of the ABT-578 eluting phosphorylcholine-coated BiodivYsio® (Abbott Vas-
cular Devices, Redwood City, CA) stent which enrolled 11 cases with de novo human cor-
onary lesions. The aim of this substudy was to evaluate the impact of this new drug-
eluting stent on both stented segment and stent edges.
Methods: Serial 3-D IVUS analysis (baseline and 3-month follow-up) was available in 9
out of 11 patients (one case was excluded due to low IVUS image quality; the other due
to additional dilatation with a non-study stent). Minimum lumen area (LA) and mean
areas for lumen, plaque (PA), stent (SA), vessel (VA) and neointima (NIA) were mea-
sured over the stented and the stent edge (both 5 mm proximal and distal adjacent to the
stent) segments.
Results: At baseline, neither significant plaque protrusion / thrombus nor edge dissec-
tion was detected. At follow-up, no late incomplete stent apposition was observed. Mean
NIA was 0.17 ± 0.32 mm2, and %NIA (100*mean NIA/mean SA) was 2.11 ± 3.96%.
Table shows serial changes in quantitative IVUS parameters.
Conclusion: Preliminary analysis of the initial human experience with the ABT-578 elut-
ing phosphorylcholine-coated stent showed no apparent adverse vessel response. The
amount of neointimal proliferation was minimum. Further studies will be needed to con-
firm these favorable observations. 
1101-63 Impact of Preinterventional Lesion Calcification on 
Neointimal Hyperplasia Following Sirolimus-Eluting 
Stent Implantation: An Intravascular Ultrasound 
Analysis
Hideaki Kaneda, Tomomi Koizumi, Junya Ako, Yasuhiro Honda, Mitsuyasu Terashima, 
Yoshihisa Shimada, Yoshihiro Morino, Paul G. Yock, Martin B. Leon, Jeffrey W. Moses, 
Peter J. Fitzgerald, The SIRIUS Investigators, Stanford University, Stanford, CA, Lenox 
Hill Hospital, New York, NY
Background: Although the negative impact of lesion calcification on stent expansion is
well known, the effect of calcification on neointimal hyperplasia (IH) following sirolimus-
eluting stent (SES) implantation is not well characterized.
Methods: Eighty-two patients who underwent SES (n=45) or bare metal stent (n=37)
implantation and preinterventional IVUS were enrolled in this substudy from the overall
SIRIUS population. Lesions were divided into calcified (defined as calcific deposits at
minimum lumen area cross section), or non-calcified. Stent, lumen, IH (stent-lumen) area
were measured at baseline and 8 month follow-up.
Results: Overall, acute lumen area gain tended to be less in calcified lesion (5.19±2.38
vs. 6.06±2.43mm2, P=0.13), resulting in smaller stent area (7.90±2.60 vs.8.70±2.56mm2,
P=0.19). There was a significant interaction between calcification and stent type on IH
suppression (Figure). However, multiple logistic regression analysis including stent type,
stent area at baseline, and plaque type showed that stent type was the only predictor for
target lesion revascularization or binary angiographic restenosis.
Conclusion: The treatment effect between sirolimus and control in reducing restenosis
remained constant, irrespective of lesion characteristics. Despite less optimal acute
results in calcified lesions, SES suppressed IH effectively. 
1101-64 Six-Month Intracoronary Ultrasound Findings Following 
Sirolimus-Eluting Stents for the Treatment of 
Restenosis-Prone Coronary Lesions
José Suárez de Lezo, Alfonso Medina, Miguel Romero, Manuel Pan, José Segura, 
Antonio Delgado, Djordje Pavlovic, Isabel Ureña, Enrique Hernández, Juan Herrador, 
Federico Segura, Francisco Melián, Reina Sofía Hospital, Córdoba, Spain, Dr. Negrín 
Hospital, Las Palmas de Gran Canaria, Spain
Background: Drug-eluting stents are promising. However, follow-up information is still
limited. Intravascular ultrasound (IVUS) is a unique tool is evaluating in situ late results.
Methods: We describe the follow-up IVUS findings obtained from 102 patients with coro-
nary lesions prone to restenosis who had been treated with sirolimus-eluting stents
(SES). Lesions were considered at risk for restenosis because of the following reasons:
in-stent restenosis, major bifurcation lesion, long-diffuse stenosis, or chronic total occlu-
sion. Sixty-two patients had more than 1 risk condition for restenosis. The mean age was
60±10 years. All patients had six-month angiographic and IVUS evaluation. Motorized
IVUS pull-back study of the treated segment was always performed. Proximal and distal
references were interrogated at 1 cm from the stent borders. Intrastent IVUS-measure-
ments were also performed. Results: Qualitatively, we observed focal non-stent apposi-
tion in 11 patients and a bulge or minor aneurysm formation in 2. Eleven patients (11%)
showed focal restenosis. In the remaining 91 patients, the stent was covered with a fine
lining. In addition, the intima was thicker at the edges showing compensatory vessel
enlargement. The table summarizes the quantitative results.
Conclusion: These findings show that adequate healing of restenosis-prone lesions
occurs in most patients. However, focal restenosis may develop. A favorable remodeling
is observed at the edges.
1101-65 Predictors of Edge Stenosis Following Sirolimus-
Eluting Stent Deployment: A Quantitative Intravascular 
Ultrasound Analysis From the SIRIUS Trial
Ryota Sakurai, Junya Ako, Shinjo Sonoda, Hideaki Kaneda, Yoshihiro Morino, Mitsuyasu 
Terashima, Ali Hassan, Paul G. Yock, Martin B. Leon, Jeffrey W. Moses, Peter J. 
Fitzgerald, Yasuhiro Honda, Stanford University, Stanford, CA
Background: While sirolimus-eluting stents (SES) have substantially reduced instent
restenosis, less efficacy at stent edges has been reported in the SIRIUS trial, a multi-
center, randomized, prospective clinical trial comparing the sirolimus-eluting Bx VELOCI-
TYTM stent to bare metal stents.
Methods: Angiographic and IVUS data were obtained from SIRIUS. To investigate possi-
ble determinants of peri-stent edge stenosis (defined as diameter stenosis greater than
50% either proximal or distal to the stent) at follow-up, baseline IVUS parameters were
analyzed in 172 edges of 92 SES.
Results: Of these, 6 edges in 6 SES had edge stenosis at 8-month follow-up. Quantita-
tive IVUS results are shown in the table.
Conclusion: The IVUS measurements of maximum stent area (SA) and edge SA com-
pared to reference suggest that overexpansion (not detected by angio balloon / artery
TLR (n=8) No TLR (n=32)
Radiation failure (%) 71 54
Lesion length (mm) 41.4±33.1 25.8±14.5
Number of stents 2.8±1.9 1.6±1.0
Residual edge lesion (%) 25 19
Reference EEM area (mm2) 9.86±6.30 9.47±4.60
Reference lumen area (mm2) 7.31±4.14 6.54±3.44
Minimum stent area (mm2) 4.32±1.98 4.71±1.68
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6.20 6.09 NS 6.42 6.83 NS 6.48 5.96 NS
Mean LA 
(mm2)
7.34 6.95 NS 8.35 8.40 NS 7.90 7.63 NS
Mean PA 
(mm2)
7.41 7.30 NS 6.30 6.06 NS 5.07 4.97 NS
Mean SA 
(mm2)
7.34 7.12 NS — — — — — —
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14.75 14.42 NS 14.65 14.46 NS 12.97 12.60 NS
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Proximal 
reference
0.5±0.2 6±3 11±5 -- 19±7
Proximal edge 0.8±0.3 8±4 9±4 -- 20±7
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-- 0.8±0.9 6.9±2.2 7.7±2.5 19±5
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